NVAX Market Cap History
Below is a table of the NVAX market cap history going back to 3/11/2010:

Date NVAX Market Cap
3/11/2010248.69M
4/30/2010284.38M
7/31/2010239.41M
10/31/2010269.98M
3/22/2011292.31M
4/30/2011288.10M
7/31/2011215.28M
10/31/2011181.66M
3/8/2012159.26M
4/30/2012166.12M
7/31/2012298.10M
10/31/2012310.68M
3/4/2013264.82M
4/30/2013358.29M
7/30/2013395.54M
10/31/2013646.38M
3/6/20141.26B
4/30/2014916.63M
7/31/20141.03B
10/31/20141.34B
2/23/20152.27B
4/30/20152.07B
7/31/20153.25B
10/31/20151.82B
2/24/20161.29B
4/30/20161.42B
7/31/20161.99B
10/31/2016412.29M
2/23/2017375.29M
4/30/2017231.74M
7/31/2017305.95M
10/31/2017341.84M
3/9/2018708.11M
4/30/2018595.41M
8/3/2018447.63M
10/31/2018673.82M
3/12/2019229.50M
4/25/2019234.73M
5/10/2019154.22M
7/31/2019103.11M
9/16/20192.16B
10/31/2019110.83M

Also see: NVAX Shares Outstanding History
and NVAX YTD Return
NVAX Historical Market Cap:
-8.04% CAGR
NVAX Historical Market Cap: +-8.04% CAGR

Mouse over chart for data details
3/11/2010 ...10/31/2019
Novavax is a late-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including its primary candidates, ResVax™ and NanoFlu™, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Co.'s product pipeline targets a variety of infectious diseases. Co. is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. Co.'s primary adjuvant, Matrix-M™, has been shown to improve immune responses and was well-tolerated in multiple clinical trials. We show 42 historical shares outstanding datapoints in our NVAX shares outstanding history coverage, used to compute NVAX market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing NVAX market cap history over the course of time is important for investors interested in comparing NVAX's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of NVAX versus a peer is one thing; comparing NVAX market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like NVAX can fluctuate over the course of history. With this page we aim to empower investors researching NVAX by allowing them to research the NVAX market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for NVAX:
NVAX SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Novavax (NVAX) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

NVIV Market Cap History
NVO Market Cap History
NVRO Market Cap History
NVTA Market Cap History
NVTR Market Cap History
NVUS Market Cap History
NXTM Market Cap History
NYMX Market Cap History
OBLN Market Cap History
OCUL Market Cap History
More Healthcare companies »

 

NVAX Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.